Dutch biopharmaceutical company Amsterdam Molecular Therapeutics‘ (AMT) lead product, Glybera, has demonstrated long-term health benefits in one-time administration for patients with acute pancreatitis.

Three-year follow-up data for the eight patients in the first clinical trial showed a statistically significant, ten-fold decrease in the incidence of acute pancreatitis.

From the second trial in 14 patients, one-year data is already showing similar results.

The data from both trials also confirm that the treatment is well tolerated and safe.